BioVaxys Technology Corp. and Adiverna LLC announced a research agreement to develop mRNA-based vaccines for rabies, leptospirosis, feline infectious peritonitis, and other diseases in companion animals. This collaboration combines Adiverna's proprietary artificial intelligence technology for designing mRNA sequences with BioVaxys' DPX immune educating platform, targeting a market where no mRNA vaccines are currently approved for dogs and cats.
Adiverna's AI platform uses machine learning algorithms and advanced bioinformatics to analyze extensive datasets, identifying optimal mRNA sequences that code for protective broadly cross-neutralizing antigens. This approach offers significant dose-sparing potential while eliciting robust immune responses. Kirill Kalnin, PhD, Founder and Chief Technology Officer of Adiverna, stated that the collaboration will revolutionize routine annual vaccinations by enhancing safety and effectiveness while reducing financial burdens on pet owners.
BioVaxys' DPX platform represents a major innovation in vaccine development, addressing limitations of other delivery methods like lipid nanoparticles. The platform uses a novel non-systemic mechanism that forces active uptake of immune cells into lymphatic nodes rather than releasing ingredients at the injection site. Kenneth Kovan, President and Chief Operating Officer of BioVaxys, explained that DPX provides enhanced stability of packaged mRNA and attracts unique subsets of antigen presenting cells for targeted immune system uptake.
Traditional companion animal vaccines typically provide protection for one to three years, with rabies vaccines usually lasting one year initially. DPX-formulated mRNA vaccines would offer superior, longer-lasting immunity with fewer doses, along with rapid and durable neutralizing antibody responses. These vaccines would eliminate viral material, reducing risks associated with injecting foreign, inactivated viruses while incorporating advantages like non-systemic depot delivery and excellent shelf-life stability.
The market potential is substantial, with the global rabies veterinary vaccines market valued at US$785 million in 2024 and projected to reach approximately US$1.1 billion by 2030, according to Research & Markets data from January 20, 2025. The broader dog vaccine market was valued at approximately $2.10 billion in 2025, while the feline vaccines sector is projected to reach USD 3.28 billion by 2034 from USD 1.77 billion in 2025, as reported by Fortune Business Insights in February 2026. Market growth is driven by mandatory pet vaccinations, increasing disease awareness, and rising pet ownership, particularly in North America and the Asia/Pacific region.
Kovan expressed excitement about developing what could be the world's first mRNA veterinary vaccine, noting that demonstrated proof of concept will advance partnering discussions for human therapeutic applications. The collaboration addresses significant challenges in current veterinary vaccines, including short durability, serotype specificity, and adverse reactions that make traditional formulations difficult to apply effectively.
